HTR2C

5-hydroxytryptamine receptor 2C · P28335 · HTR2C on Sugi Atlas →

669,453 patent compounds predicted against HTR2C, 387,348 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Epinastine (SCHEMBL18794)	0.45	12/20
SCHEMBL13777	0.57	11/20
SCHEMBL13778	0.57	11/20
SCHEMBL4574	0.59	10/20
Rizatriptan (SCHEMBL26662)	1.00	9/20
Serotonin (SCHEMBL1495)	1.00	7/20
Sumatriptan (SCHEMBL1482)	1.00	6/20
Ergotamine (SCHEMBL1483)	1.00	6/20
Amitriptyline (SCHEMBL7824)	1.00	6/20
Prochlorperazine (SCHEMBL18429)	1.00	6/20
Ergotamine (SCHEMBL8045)	0.93	6/20
Ergotamine (SCHEMBL8046)	0.93	6/20
SCHEMBL3472	0.64	6/20
Mianserin (SCHEMBL18020)	1.00	5/20
Olanzapine (SCHEMBL28763)	1.00	5/20
Tegaserod (SCHEMBL27215)	0.70	5/20
Tegaserod (SCHEMBL16464)	0.67	5/20
SCHEMBL12822	0.41	5/20
Propranolol (SCHEMBL3955)	1.00	4/20
Levopropranolol (SCHEMBL3956)	1.00	4/20

Clinical trials — most relevant to HTR2C by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Study on the Efficacy of Agomelatine Combined With Antipsychotics to Treat Negative Symptoms in Schizophrenia	PHASE4	UNKNOWN
The Relationship Among Changes in Brain Network Activation in Adult Outpatients With Major Depressive Disorder	PHASE4	COMPLETED
Medication, Weight Gain and GI Hormones	PHASE4	COMPLETED
Clinical Neurobiology of Serotonin and Addiction	PHASE2/PHASE3	COMPLETED
Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression	PHASE1/PHASE2	RECRUITING
5HT2CR Balance in Brain Connectivity in Cocaine Dependence	PHASE1/PHASE2	COMPLETED
Lorcaserin Intra Venous Cocaine Effects	PHASE1/PHASE2	UNKNOWN
Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder	PHASE2	RECRUITING
Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ)	PHASE2	NOT_YET_RECRUITING
Clinical, Neurocognitive, and Emotional Effects of Psilocybin in Depressed Patients - Proof of Concept	PHASE2	COMPLETED
Pimavanserin and Aggression and Social Cognition.	PHASE2	RECRUITING
Effects of SERT Inhibition on the Subjective Response to Psilocybin in Healthy Subjects	PHASE1	COMPLETED
The Neurobiological Effect of 5-HT2AR Modulation	PHASE1	RECRUITING
Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects	PHASE1	COMPLETED
SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis	EARLY_PHASE1	UNKNOWN
Mood Effects of Serotonin Agonists: Depression	EARLY_PHASE1	RECRUITING
Trazodone and the Risk of Serious Adverse Events	nan	COMPLETED
Epigenetic and Neurochemical Correlates of Bipolar Disorder	nan	NOT_YET_RECRUITING
Investigating the Neuropsychological Effects of 5-HT2a Antagonism	nan	RECRUITING
Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis	nan	COMPLETED
The Efficacy of Tianeptine Versus Pregabalin on Acute and Chronic Post Mastectomy Pain After Breast Cancer Surgery.	nan	COMPLETED
Microdosing LSD in Women With Premenstrual Disorders	nan	NOT_YET_RECRUITING
The Role of 5-HT2A Receptor in the Perception of Self and Personal Meaning in Healthy Volunteers	nan	COMPLETED
Evaluation of [11C]Cimbi-36 as an Agonist PET Radioligand for Imaging of 5-HT2A Receptors	nan	COMPLETED
The Pill Project - Oral Contraceptive and Serotonergic Brain Signaling	nan	UNKNOWN
A Single-Blind Trial of Risperidone vs. Paroxetine for Treatment of Panic Attacks	nan	COMPLETED
Agomelatine in Depressed Patients With Fibromyalgia	nan	COMPLETED
Genetic Variants Associated With Adolescent Suicide Attempts	nan	COMPLETED
Examination of Brain Serotonin Receptors in Patients With Mood Disorders	nan	COMPLETED
Imaging Serotonin 5HT1A Receptors in Patients With Major Depressive Disorder	nan	WITHDRAWN

Related proteins — ESM-2 sequence neighbours (a HTR2C binder may also engage these)

Protein	Name	Similarity
Q5IS66	—	1.000	Q5IS66 →
P34968	—	1.000	P34968 →
Q60F97	—	1.000	Q60F97 →
P08909	—	0.997	P08909 →
O46635	—	0.996	O46635 →
Q75Z89	—	0.994	Q75Z89 →
P50129	—	0.994	P50129 →
P18599	—	0.994	P18599 →
P35363	—	0.993	P35363 →
Q8UUG8	—	0.991	Q8UUG8 →
Q9N2A4	—	0.988	Q9N2A4 →
P14842	—	0.987	P14842 →
Q02152	—	0.987	Q02152 →
HTR2A	5-hydroxytryptamine receptor 2A	0.986	landscape →
P08911	—	0.985	P08911 →
P50128	—	0.985	P50128 →
P42288	—	0.985	P42288 →
Q5R4Q6	—	0.984	Q5R4Q6 →
P97718	—	0.984	P97718 →
CHRM5	Muscarinic acetylcholine receptor M5	0.983	landscape →
P30994	—	0.983	P30994 →
Q95136	—	0.983	Q95136 →
P08483	—	0.983	P08483 →
O73810	—	0.983	O73810 →
P50130	—	0.983	P50130 →
Q920H4	—	0.982	Q920H4 →
Q8ITC7	—	0.982	Q8ITC7 →
P41984	—	0.981	P41984 →
P42289	—	0.981	P42289 →
Q9ERZ3	—	0.980	Q9ERZ3 →